First Berlin Equity Research Sets Jaguar Health Price Target at $7.50 with Buy Rating

Reuters

Feb 12

<a href="https://laohu8.com/S/FTFI">First Berlin</a> Equity Research Sets Jaguar Health Price Target at $7.50 with Buy Rating

First Berlin Equity Research has released an updated report on Jaguar Health Inc., reiterating its BUY recommendation while lowering the 12-month price target from USD 35.00 to USD 7.50. Analyst Christian Orquera cites Jaguar Health’s recent U.S. licensing agreement with Future Pak for Mytesi and Canalevia-CA1, which secures $18 million in upfront cash payments and up to $20 million in milestone and other payments. The agreement is expected to significantly improve Jaguar Health’s liquidity and reduce commercial risk in the U.S. market. The revised price target reflects updated assumptions, including higher dilution following balance sheet adjustments and the recent share price decline, but maintains a strong upside potential for the stock.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: rc_24668), on February 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610927481"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610927481\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610927481?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-12 22:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610927481","market":"us","top_or_hot":-1,"title":"First Berlin Equity Research Sets Jaguar Health Price Target at $7.50 with Buy Rating","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/FTFI\">First Berlin</a> Equity Research Sets Jaguar Health Price Target at $7.50 with Buy Rating\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        First Berlin Equity Research has released an updated report on Jaguar Health Inc., reiterating its BUY recommendation while lowering the 12-month price target from USD 35.00 to USD 7.50. Analyst Christian Orquera cites Jaguar Health’s recent U.S. licensing agreement with Future Pak for Mytesi and Canalevia-CA1, which secures $18 million in upfront cash payments and up to $20 million in milestone and other payments. The agreement is expected to significantly improve Jaguar Health’s liquidity and reduce commercial risk in the U.S. market. The revised price target reflects updated assumptions, including higher dilution following balance sheet adjustments and the recent share price decline, but maintains a strong upside potential for the stock.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: rc_24668), on February 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>First Berlin Equity Research Sets Jaguar Health Price Target at $7.50 with Buy Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFirst Berlin Equity Research Sets Jaguar Health Price Target at $7.50 with Buy Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-12 22:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/FTFI\">First Berlin</a> Equity Research Sets Jaguar Health Price Target at $7.50 with Buy Rating\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        First Berlin Equity Research has released an updated report on Jaguar Health Inc., reiterating its BUY recommendation while lowering the 12-month price target from USD 35.00 to USD 7.50. Analyst Christian Orquera cites Jaguar Health’s recent U.S. licensing agreement with Future Pak for Mytesi and Canalevia-CA1, which secures $18 million in upfront cash payments and up to $20 million in milestone and other payments. The agreement is expected to significantly improve Jaguar Health’s liquidity and reduce commercial risk in the U.S. market. The revised price target reflects updated assumptions, including higher dilution following balance sheet adjustments and the recent share price decline, but maintains a strong upside potential for the stock.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: rc_24668), on February 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL39SZ7s:1","article_id":"2610927481","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610927481","pubTimestamp":1770907675,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"First Berlin Equity Research has released an updated report on Jaguar Health Inc., reiterating its BUY recommendation while lowering the 12-month price target from USD 35.00 to USD 7.50. Analyst Christian Orquera cites Jaguar Health’s recent U.S. licensing agreement with Future Pak for Mytesi and Canalevia-CA1, which secures $18 million in upfront cash payments and up to $20 million in milestone and other payments. The agreement is expected to significantly improve Jaguar Health’s liquidity and reduce commercial risk in the U.S. market. The revised price target reflects updated assumptions, including higher dilution following balance sheet adjustments and the recent share price decline, but maintains a strong upside potential for the stock.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","JAGX":"Jaguar Animal Health, Inc."},"translate_title":"First Berlin Equity Research将Jaguar Health目标价定为7.50美元，给予买入评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JAGX":0.9},"content_text":"First Berlin Equity Research Sets Jaguar Health Price Target at $7.50 with Buy Rating\n    \n\n        First Berlin Equity Research has released an updated report on Jaguar Health Inc., reiterating its BUY recommendation while lowering the 12-month price target from USD 35.00 to USD 7.50. Analyst Christian Orquera cites Jaguar Health’s recent U.S. licensing agreement with Future Pak for Mytesi and Canalevia-CA1, which secures $18 million in upfront cash payments and up to $20 million in milestone and other payments. The agreement is expected to significantly improve Jaguar Health’s liquidity and reduce commercial risk in the U.S. market. The revised price target reflects updated assumptions, including higher dilution following balance sheet adjustments and the recent share price decline, but maintains a strong upside potential for the stock.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: rc_24668), on February 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}